Disease Landscape and Forecast Insights

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the…

Multiple well-established therapies are currently available to treat ulcerative colitis (UC) in Europe. TNF-α inhibitors such as Janssen / Merck’s Remicade and AbbVie / Eisai’s Humira helped…

The biosimilar/noninnovator sector of the endocrinology market is evolving. Eli Lilly/Boehringer Ingelheim’s Abasaglar/Basaglar was the first biosimilar/noninnovator insulin glargine to launch in…

The treatment of renal cell carcinoma has long been dominated by targeted treatments, including mTOR and angiogenesis inhibitors. However, the introduction of immune checkpoint inhibitors has…

Since the approval of the first biosimilar in Europe more than a decade ago, the use of biosimilars has been increasing in that region. Likewise, the FDA approved the first biosimilar in 2015, and…

Glomerulonephritis (GN) is a broad term covering various conditions involving injury and inflammation of the glomerulus, which plays an important role in the filtration of blood in the kidney. As…

Hormonal therapies have dominated the treatment of prostate cancer for the past decade. Zytiga (Janssen, generics) and Xtandi (Medivation / Astellas Pharma), initially approved for metastatic…

The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…

A variety of analgesic products are available to specialists managing postoperative pain in the United States, although the majority of these medicines are available as inexpensive generics…

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL…

MARKET OUTLOOK The current treatment algorithm for NSCLC is dominated by targeted branded therapies, reflecting its biomarker-driven treatment landscape. The EGFR and ALK TKIs Tagrisso and…

The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include…